LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB
Publication
, Conference
O'Connor, OA; Flinn, I; Lunning, M; Vose, J; Fowler, N; Nastoupil, L; O'Brien, S; Schreeder, MT; Patel, MR; Fenske, TS; Brander, DM; Kuhn, JG ...
Published in: HAEMATOLOGICA
June 1, 2016
Duke Scholars
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2016
Volume
101
Start / End Page
102 / 103
Location
Copenhagen, DENMARK
Publisher
FERRATA STORTI FOUNDATION
Conference Name
21st Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Connor, O. A., Flinn, I., Lunning, M., Vose, J., Fowler, N., Nastoupil, L., … Burris, H. A. (2016). LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In HAEMATOLOGICA (Vol. 101, pp. 102–103). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
O’Connor, O. A., I. Flinn, M. Lunning, J. Vose, N. Fowler, L. Nastoupil, S. O’Brien, et al. “LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.” In HAEMATOLOGICA, 101:102–3. FERRATA STORTI FOUNDATION, 2016.
O’Connor OA, Flinn I, Lunning M, Vose J, Fowler N, Nastoupil L, et al. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 102–3.
O’Connor, O. A., et al. “LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.” HAEMATOLOGICA, vol. 101, FERRATA STORTI FOUNDATION, 2016, pp. 102–03.
O’Connor OA, Flinn I, Lunning M, Vose J, Fowler N, Nastoupil L, O’Brien S, Schreeder MT, Patel MR, Fenske TS, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Burris HA. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 102–103.
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2016
Volume
101
Start / End Page
102 / 103
Location
Copenhagen, DENMARK
Publisher
FERRATA STORTI FOUNDATION
Conference Name
21st Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology